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1. Introduction  
Normocalcemic primary hyperparathyroidism is a new entity which possibly represents a 
fruste form of the classic clinically symptomatic disease and which has generated a 
considerable scientific interest in the last decade. Its official recognition is just as recent as in 
2008, when an international conference took place for clarifying its nature and relevance 
(Bilezikian et al., 2009). Its true prevalence is mostly unknown although it is clear that it is 
recognized more and more in different clinical settings, from internal medicine outpatient 
clinics to endocrine or rheumatologists consultations. It is a challenging situation for either 
the clinician and the patient, as therapeutic recommendations are nowadays nor established 
and different patients may be advised to receive certain active treatment or just follow-up, 
or even no follow-up. In this chapter the current data in relation to this emergent condition 
are presented.  
2. Definition and biochemical considerations 
Normocalcemic primary hyperparathyroidism (NPHPT) is defined by a situation in which 
persistently normal serum calcium levels are observed in the presence of high levels of 
parathyroid hormone (PTH). The term normocalcemic primary hyperparathyroidism was 
first used in the decade of the 60’s by Wills (Wills et al., 1967), who described a group of 
patients with characteristics different from those with classic primary hyperparathyroidism 
in which the patients presented a paucity of clinical symptoms and signs and hypercalcemia 
was absent. No other terms have been used, such as subclinical hyperparathyroidism or low 
grade primary hyperparathyroidism have been used in the definition of this condition, as it 
has been the case for similar endocrine disturbances like i.e. subclinical hypothyroidism. The 
definition of normocalcemic primary HPT’ includes total albumin-corrected serum calcium 
within the normal range and serum parathyroid hormone (PTH) relatively elevated in 
comparison to the serum calcium level. 
Under such a biological combination a search for causes that may reveal a secondary 
hyperparathyroidism syndrome is the first step that the clinician uses to face, and mostly all 
situations that could favor vitamin D deficiency, a condition very prevalent all over the 
world (Silverberg et al., 2009), need to be ruled out. In fact this is a major problem, as in 
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most cases it is not known if the reference range of a given PTH assay has been made with a 
population in which vitamin D deficiency exclusion criteria has been considered. PTH is a 
heterogeneous molecule, and in the last 25 years its measurement has been performed with 
different assays which have been experimented technological evolution. We have been 
using different generations of assays and currently we under in the third generation era; the 
sensitivity of second- and third generation PTH assays in detecting elevated PTH values 
seems to be similar (Eastell R et al., 2009). By using a second-generation PTH assay it has 
been recognized how important it is to exclude subjects with low serum 25OHD levels in 
establishing a reference range for PTH (Souberbielle JC et al., 2001). When this is taken into 
account, the upper limit of the PTH reference interval for second-generation assays 
decreased from 65 to 46 ng/liter, a 29% reduction. The same applies for establishing a 
reference interval for “whole PTH” assays the upper limit decreasing from 44 to 34 ng/L, a 
27% reduction; finally, the upper limit of the reference interval remains also lower for third 
generation assays than for second-generation ones. It has to be mentioned that in parallel, 
vitamin D references values have been established in the last decades, and moreover, there 
is still a debate going on in relation to what are the lower normal values (Looker et al., 2008). 
In some studies, values below 20 ng/mL were taken as the lower limit of vitamin D 
sufficiency, whereas other studies have reported that PTH levels in normocalcemic 
individuals continue to decline until levels of 25OHD above 30 ng/ml have been achieved 
(Chapuy et al., 1992, 2002; Dawson-Hughes et al., 1997). This emphasizes the importance of 
establishing an international consensus on a reference range for 25OHD, if we are to 
improve the reference range of PTH by excluding subjects with vitamin D insufficiency. A 
very interesting approach has been recently proposed by Harvey et al (Harvey A et al., 
2011), by using a nomogram in which vitamin D and age are included for refining the 
diagnosis of primary hyperparathyroidism. 
3. Epidemiology 
There is virtually no data in relation to the epidemiology of NPHPT. Lundgren and cols. 
(Lundgren E et al., 2002; Tordjman et al., 2004) studied more than 5,000 postmenopausal 
women between the ages of 55 and 75 in Swedish survey. They found that 16% of 
individuals had normal serum calcium levels (< 9.9 mg/dL) and elevated PTH. This group 
included both those with vitamin D deficiency which was not ruled out and non-deficient 
cases which could effectively considered as the true cases of normocalcemic PHPT. Taken 
together both situations, the prevalence seems really surprising and thus will imply that this 
disorder is the most prevalent endocrine disorder so far. More data are warranted in order 
to confirm such a potential high prevalence. 
4. Clinical presentation 
It is not known if NPHPT is an indolent disease or if it may have an impact similar, to certain 
extent, to the classic primary hyperparathyroidism bone metabolism dysfunction and renal 
damage as a consequence of sustained circulating increased PTH. It is also not known if 
increased PTH per se may have pathological consequences as the disorder goes on –if it would 
be true that progression is universal in all cases- and if therapeutic intervention aimed to 
normalize PTH may have any benefit at short and long term in these patients. Therefore it is 
very important to conduct studies in order to clarify all this lack of information.  
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Usually, NPHPT is discovered in the context of an evaluation of patients with low bone 
density in specialized metabolic bone units, in whom secondary causes for increased PTH 
concentration have been carefully ruled out. However, some patients can present with some 
clinical features of classical hyperparathyroidism, such as fragility fracture and kidney 
stones. Lowe et al. (Lowe et al., 2007) evaluated thirty-seven patients who met criteria of 
NPHPT. At the moment of presentation, 14% of the patients had a history of nephrolithiasis 
and 46 % had a history of fracture in adulthood.  Bone mineral density assessment showed 
that 57% had osteoporosis in at least one site (lumbar-spine, hip or distal radius), 19% had 
osteoporosis at two of three sites and 8% were osteoporotic at all three sites.  Osteoporosis 
was more common at the lumbar spine (34%) and hip (38%) than in the distal radius (28%), 
in contrast to the hypercalcemic form of hyperparathyroidism, where preponderance of 
bone density loss more at the cortical radius site is observed. 
 There are few studies that evaluated the evolution of this entity at long term. These patients 
are at some risk of disease progression, further developing features of classical 
hyperparathyroidism in certain cases. Also, some of these patients will become 
hypercalcemic over time, and it is observed that those with the higher serum calcium 
average concentrations and those who were somewhat older were more likely to develop 
hypercalcemia. On the other hand, some of these patients will suffer from kidney stones, 
decline in BMD, osteoporosis, and even fractures. 
In the cohort of Lowe et al. (Lowe et al., 2007) 41% of the patients showed evidence for 
progressive hyperparathyroid disease at a median follow up of 3 years: 19% became 
hypercalcemic, 3% presented kidney stones, 29 % presented progressive cortical bone loss 
(occurring at all sites) and decline of BMD greater than 10% in 16%; 11% presented new 
osteoporotic lesions and 3% bone fracture. But on the other side, they also observed that 
some of the patients with the longest follow up (8 years) did not show evidence of disease 
progression and may never develop the more typical hypercalcemic phenotype of the 
disease. Therefore, in some patients there is a progression of the disease and in some other 
not, and until now there is no way to segregate both cohorts and prediction of progression is 
not currently feasible. 
Overt primary hyperparathyroidism is associated with an increased frequency of 
dyslipidemia, hypertension, overweight and impaired glucose tolerance. It remains unclear 
whether NPHPT goes together with such cardiovascular risk factors seen in a much active 
hyperparathyroid situation when circulating calcium is high. There is very few information in 
NPHPT and in the only study performed so far (Hagström et al., 2006) some degree of 
relationship seems to exist although vitamin D deficiency was not assessed in this cohort and it 
is very well known how important vitamin D sufficiency for cardiovascular protection is 
(Adams & Hewison., 2010 ). The relevance of this latter study (Hagström et al., 2006) is that is 
was performed in general population, while most of the data of NPHPT have been obtained in 
subjects which have received medical attention mostly because of bone or kidney problems, 
implying a bias in the interpretation of the non symptomatic nature of this entity. 
NPHPT has a pleiotropic phenotypic presentation and nowadays it remains unclear whether it 
could be the initial phase or and indolent form of classic hyperparathyroidism. Data suggest 
that it is not the early stage of mild asymptomatic hyperparathyroidism but it could be the 
earliest form of symptomatic hyperparathyroidism, where the patients have already 
developed some signs and symptoms of the disease but show normal serum calcium 
concentration, suggesting that this entity may not be as indolent as previously though. 
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5. Treatment of asymptomatic HPT 
Currently there are no guidelines for the management of NPHPT. Even asymptomatic HPT 
(defined as hyperparathyroidism that lacks specific symptoms or signs traditionally 
associated with hypercalcemia) treatment is a controversial subject. Third Workshop on the 
Management of Asymptomatic Primary Hyperparathyroidism in 2009 tried to clarify 
surgical/medical versus follow up management depending on severity of the 
manifestations of disease and age of the patient (Bilezikian et al, 2009). 
From First Workshop on the Management of Asymptomatic Primary Hyperparathyroidism 
in 1990 to present time surgical indications have been changing to an earlier parathyroid 
surgery (Table 1).  
 
 1990 2002 2008 
Serum Calcium 
(>upper limit of 
normal) 
1-1.6 mg/dl 
(0.25-0.4 
mmol/l) 
1.0 mg/dl (0.25 
mmol/l) 
1.0 mg/dl (0.25 
mmol/l) 
24 h urinary for 
calcium 
>400 mg/d 
(>10 mmol/d) 
>400 mg/d (>10 
mmol/d) 
Not recommended 
Creatinine 
clearance 
(calculated) 
Reduced 30% Reduced 30% 
Reduced to < 60 
ml/min 
BMD 
Z-score  < -2.0 
in forearm 
T score <-2.5 at any 
site 
T score <-2.5 at any 
site and/or previous 
fracture fragility 
Age (year) <50 <50 <50 
Table 1. Evolution of guidelines recommendations for parathyroid surgery in asymptomatic 
HPT (Bilezikian et al, 2009) 
However, pharmacologic approach to management of asymptomatic HPT (selected estrogen 
receptor modulators, biphosphonates and calcimimetics) is limited to patients in whom 
surgical treatment is not possible mostly because of surgical risk but in whom serum 
calcium levels or BMD should be treated.  
Anyway, Third Workshop concluded that although surgery is an attractive and definitive  
choice it is also recognized that medical management can be appropriate in those who do 
not meet surgical indications or are unable or unwilling to proceed with parathyroidectomy.  
For those cases, follow-up is adviced by Third Workshop (table 2) 
 
 1990 2002 2008 
Serum Calcium Biannually Biannually Annually 
24 h urinary calcium Annually Not recommended Not recommended 
Creatinine clearance  
(24 h collections) 
Annually Not recommended Not recommended 
Serum creatinine Annually Annually Annually 
Bone density 
Annually 
(forearm) 
Annually (3 sites) 
Every 1-2 years  
(3 sites) 
Abdominal X ray (ultrasound) Annually Not recommended Not recommended 
Table 2. Evolution of management guidelines for patients with asymptomatic primary 
hyperparathyroidism who do not undergo parathyroidectomy. (Bilezikian et al, 2009) 
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5.1.1 Surgical treatment of asymptomatic HPT 
Current guidelines to surgical management of Asymptomatic HPT include (Table 1) (Udelsman 
et al, 2009): 
1. Serum calcium threshold 1 mg/dl (0.25 mM/liter) above the upper limits of normal range. 
2. Peri – Postmenopausal men and women older than 50, with T score of 2.5 or less at the 
lumbar spine, femoral neck, total hip, or 33% (one third) radius. In premenopausal 
women and in men younger than 50, the Z-score of 2.5 or less is recommended as the 
cutpoint. 
3. Age less than 50 years old 
4. A GFR less than 60ml/min.1.73m2 defined a stage 3 level of renal insufficiency 
according to the K/DOQI guidelines. 
As main change with other consensus statement hypercalciuria in the absence of renal 
stones or nephrolithiasis, is no longer regarded as an indication for parathyroid surgery as it 
presence without any other factors has not been established as a kidney stone risk factor.  
Asymptomatic HPT has been related to neurocognitive compromise, bone density and 
fracture risk, nephrolitiasis, even with cardiovascular risk and survival. Unfortunately, the 
scientific evidence in this area is low. Clinical trials are needed to demonstrate the 
improvements in these parameters after parathyroidectomy.  
Surgical experience is the main variable to avoid surgery complications in 
parathyroidectomy, Therefore number of cases per year is the most important predictor of 
clinical outcomes. The type of operative procedure and the employment of operative 
adjuncts is highly institution specific and should be based on the expertise and resource 
availability of the surgeon and institution. 
Localization techniques of enlarged parathyroid gland (sestamibi scan, CT scan, MRI, 
between others) have a secondary role on parathyroid surgery and it is confined to 
localization assistance, never for diagnosis purpose.  
99mTC-Sestamibi is probably the most used and sensitive probe to parathyroid localization. Its 
main characteristic is the capacity of diagnosis of ectopic parathyroid glands and functional 
information. Neck ultrasound plays a principal role on thyroid nodule and parathyroid gland 
enlargement evaluation but it is highly dependent on experience and interest of the radiologist 
performing the study (Soto Gd et al, 2010). Combination of both non invasive techniques as 
complementary methods are highly recommended because of its safety and sensitive. 
In special circumstances other imaging techniques could be of interest (CT scan, MRI, PET 
scan); even, invasive procedures as parathyroid fine needle aspiration and arteriography 
and selective venous sampling for PTH. However, all these procedures are expensive, time 
consuming, and with limited but not negligible risks. Actually, its used is limited to 
minimally invasive surgery where localization parathyroid gland is essential and in those 
cases without information in conventional techniques (Udelsman et al, 2009). 
5.1.2 Medical treatment of asymptomatic HPT 
To the date, pharmacologic approach to management of asymptomatic HPT  is limited to 
patients in whom surgical treatment is not possible because of surgical risk but in whom 
serum calcium levels or BMD should be treated.  
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Selective estrogen receptor modulators and bisphosphonates could be of interest in 
Asymptomatic HPT treatment because of potential BMD increase and fracture risk 
reduction. Unfortunatelly, none of this treatment have been evaluated in clinical assays 
neither in hyperparathyroidism nor HPHPT (Khan et al, 2009). Only  alendronate treatment 
was shown to improve BMD in lumbar spine of patients with primary hyperparthyroidism 
without changes in calcium levels to a degree comparable both to their effects in eucalcemic 
populations (Khan et al, 2004) What is more, fracture outcome date are not available until 
now with any of the treatments evaluated. 
Calcimimetics is a new pharmacology class that acts as an allosteric modulator of the 
calcium sensing receptor (CASR) acting to sensitize this receptor to the extracellular calcium. 
Cinacalcet has been shown to be effective in reducing or normalizing serum calcium levels 
in several groups of patients with primary hyperparathyroidism with slightly reduces PTH 
levels and no effects on bone mineral density (Peacock et al, 2005 & Marcocci et al, 2011). 
Unfortunatelly, there are no data as to whether long term treatment with cinacalcet can 
prevent the complications of PHPT.  
At present, medical treatment is limited for those individuals with Asymptomatic HPT who 
are unable to undergo corrective surgery for whom skeleton protection is the primary 
reason for intervention (biphosphonates) or control of serum calcium levels are required 
(cinacalcet). Further investigation is required in this field  
6. Conclusion  
Normocalcemic primary hyperparathyroidism is a new entity which possibly represents a 
fruste form of the classic clinically symptomatic disease and which has generated a 
considerable scientific interest in the last decade. It is a challenging situation for either the 
clinician and the patient, as therapeutic recommendations are nowadays nor established and 
different patients may be advised to receive certain active treatment or just follow-up, or even 
no follow-up. Further investigation is required to select the best treatment for each patient.   
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